Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN), a clinical-stage neuromuscular disease company, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a virtual fireside chat scheduled for Tuesday, February 11, 2025, at 4:00 p.m. ET.

Interested parties can access a live webcast of the presentation through the Investors & Media section of Dyne's website. The presentation recording will remain available for 90 days following the event on the company's investor relations platform at https://investors.dyne-tx.com/news-and-events/events-and-presentations.

News Market Reaction – DYN

-2.46%

-2.46% Session move

In the trading session that priced this news, DYN declined 2.46%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook. 

Contacts:

Investors
Mia Tobias
ir@dyne-tx.com

Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938

FAQ

When is Dyne Therapeutics (DYN) presenting at the Oppenheimer Healthcare Conference 2025?

Dyne Therapeutics is scheduled to present at the Oppenheimer Healthcare Conference on Tuesday, February 11, 2025, at 4:00 p.m. ET.

How can investors watch Dyne Therapeutics' (DYN) Oppenheimer Conference presentation?

Investors can watch the presentation through a live webcast available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations.

How long will the replay of DYN's Oppenheimer Conference presentation be available?

The replay of Dyne Therapeutics' presentation will be accessible for 90 days following the February 11, 2025 presentation.

What type of presentation will DYN deliver at the Oppenheimer Healthcare Conference 2025?

Dyne Therapeutics will participate in a virtual fireside chat format presentation at the conference.